Common Side Effects of Mounjaro 5 mg
Mounjaro (tirzepatide), a GLP-1/GIP receptor agonist for type 2 diabetes and weight management, causes gastrointestinal issues most often at the 5 mg dose. These affect over 5% of users and typically improve over time or with dose adjustment:
- Nausea (12-18% of patients)
- Diarrhea (12-17%)
- Decreased appetite (10-11%)
- Vomiting (5-9%)
- Constipation (6-7%)
- Dyspepsia (indigestion, 8%)
- Abdominal pain (5-6%)
These occur due to slowed gastric emptying, peaking in the first 4-8 weeks.[1][2]
Serious Side Effects and Risks
Rare but severe effects require immediate medical attention:
- Pancreatitis (inflammation of the pancreas; symptoms include severe abdominal pain radiating to the back)
- Gallbladder problems (cholecystitis or cholelithiasis, 0.6-1.7%)
- Acute kidney injury (from dehydration due to GI effects)
- Hypersensitivity reactions (rash, itching, swelling)
- Thyroid C-cell tumors (boxed warning based on rodent studies; human risk unclear)
- Hypoglycemia (low blood sugar, especially with insulin or sulfonylureas; 4-19% when combined)
The 5 mg dose has a similar profile to higher doses, but incidence rises with escalation.[1][3]
How Side Effects Differ by Dose
At 5 mg (maintenance starting dose after 2.5 mg titration), GI effects are milder than at 10-15 mg. Clinical trials showed nausea dropping from 22% at 5 mg to 10% with continued use. Discontinuation due to side effects occurs in 4-7% overall, lowest at lower doses.[2][4]
What Happens If You Experience Side Effects
Most resolve with hydration, anti-nausea meds, or slower titration. Doctors recommend taking with food or at bedtime. Severe cases may need dose reduction or stopping. Long-term data (up to 72 weeks) shows tolerance develops in 70-80% of patients.[1][3]
Patient Concerns and Management Tips
Users report fatigue, heartburn, or "Ozempic face" (facial sagging from rapid weight loss, though less common at 5 mg). Monitor blood sugar closely. Not for type 1 diabetes or history of medullary thyroid carcinoma. Pregnancy: discontinue 2 months prior.[2]
Sources
[1]: Mounjaro Prescribing Information (FDA)
[2]: Eli Lilly SURMOUNT-1 Trial Data
[3]: Drugs.com Mounjaro Side Effects
[4]: ClinicalTrials.gov SURPASS Studies